Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
Authors:
- Neil R. ParikhNPNeil R. Parikh
- Claudia HuizaCHClaudia Huiza
- Jill S. PatelJPJill S. Patel
- Sonny TsaiSTSonny Tsai
- Nathisha KalpageNKNathisha Kalpage
- May TheinMTMay Thein
- Sage PitcherSPSage Pitcher
- Steve P. LeeSLSteve P. Lee
- Warren S. InouyeWIWarren S. Inouye
- Mark L. JordanMJMark L. Jordan
- Homayoon SanatiHSHomayoon Sanati
- Lida JafariLJLida Jafari
Open Access
- 1 April 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-6
Abstract
The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor therapy, and metastasis-directed therapy. The impact of combining such therapies into a multimodal approach is unknown. This Phase II single-arm clinical trial sponsored and funded by Veterans Affairs combines local, metastasis-directed, and systemic therapies to durably render patients free of detectable disease off active therapy. Patients with newly-diagnosed M1a/b prostate cancer (PSMA PET/CT staging is permitted) and 1–5 radiographically visible metastases (excluding pelvic lymph nodes) are undergoing local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present. The primary endpoint is the percent of patients achieving a serum PSA of < 0.05 ng/mL six months after recovery of serum testosterone ≥150 ng/dL. Secondary endpoints include time to biochemical progression, time to radiographic progression, time to initiation of alternative antineoplastic therapy, prostate cancer specific survival, health related quality-of-life, safety and tolerability. To our knowledge, this is the first trial that tests a comprehensive systemic and tumor directed therapeutic strategy for patients with newly diagnosed oligometastatic prostate cancer. This trial, and others like it, represent the critical first step towards curative intent therapy for a patient population where palliation has been the norm. Clinicaltrials.gov identifier: NCT03298087 (registration date: September 29, 2017).Keywords
Funding Information
- U.S. Department of Veterans Affairs (1I01CX001575)
- Prostate Cancer Foundation (Young Investigator Award)
This publication has 18 references indexed in Scilit:
- Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD TrialEuropean Urology, 2019
- Treatment of the primary tumor in metastatic prostate cancerWorld Journal of Urology, 2018
- Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- Apalutamide Treatment and Metastasis-free Survival in Prostate CancerNew England Journal of Medicine, 2018
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II TrialJournal of Clinical Oncology, 2018
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2017
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNew England Journal of Medicine, 2017
- Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional AnalysisEuropean Urology, 2016
- Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)European Urology, 2015
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011